Biotage AB launches share buy-back
The board of directors of Biotage AB (publ) has resolved to start a share buy-back program in accordance with the Annual General Meeting’s resolution to authorize the board to decide on the acquisition and sale of the company’s own shares.
At the Annual General Meeting held on 25 April 2013, the board was authorized to decide on the acquisition and sale of the company’s own shares up and until the forthcoming Annual General Meeting. The shares acquired may not exceed 10 per cent of the total number of outstanding Biotage shares at any time. The purpose of the repurchase program is to give the board a wider freedom of action in the work with the company’s capital structure and thereby improve shareholder value. Acquisition and sale of shares will take place on the NASDAQ OMX Stockholm at a price within the price interval at any time recorded. Biotage currently owns 3,394,375 of its own shares, which the Annual General Meeting held on 25 April 2013 resolved to withdraw. Following the completion of the withdrawal of these shares, the total number of outstanding shares will be 69,861,330.
Torben Jörgensen, President and CEO
Tel: +46 707 49 05 84, email@example.com
Biotage discloses the information provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 1pm on 26 April 2013.
Biotage offers solutions, knowledge and experience in the areas of analytical chemistry, medicinal chemistry, separation and purification. The customers include pharmaceutical and biotech companies, companies within the food industry and leading academic institutes. The company is headquartered in Uppsala and has offices in the US, UK, China and Japan. Biotage has approx. 290 employees and had sales of 463 MSEK in 2012. Biotage is listed on the NASDAQ OMX Nordic Stockholm stock exchange. Website: www.biotage.com